Ralph Bax
Overview
Explore the profile of Ralph Bax including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karres D, Pino-Barrio M, Benchetrit S, Benda N, Cochat P, Galluzzo S, et al.
Br J Pharmacol
. 2024 Nov;
182(3):484-494.
PMID: 39574299
Drug development for children presents unique challenges and is highly regulated. Novel approaches, such as the use of extrapolation to address, for example, the need to avoid unethical studies, whilst...
2.
Epps C, Bax R, Croker A, Green D, Gropman A, Klein A, et al.
Ther Innov Regul Sci
. 2022 Apr;
56(6):964-975.
PMID: 35471559
The literature thoroughly describes the challenges of pediatric drug development for rare diseases. This includes (1) generating interest from sponsors, (2) small numbers of children affected by a particular disease,...
3.
Karres D, Reaman G, Ligas F, Lesa G, McCune S, Malli S, et al.
Ther Innov Regul Sci
. 2021 Sep;
55(6):1109-1110.
PMID: 34498227
The European Medicines Agency and the US Food and Drug Administration recently published a common commentary document on paediatric oncology drug development, building on the call for simultaneous submissions of...
4.
Slater R, Moultrie F, Bax R, van den Anker J, Bhatt A
Lancet
. 2020 Sep;
396(10255):872-873.
PMID: 32979963
No abstract available.
5.
Baum V, Bax R, Heon D, Yang Z, Sakiyama M
Paediatr Anaesth
. 2019 Mar;
29(6):572-582.
PMID: 30924233
There was a time when the predominant approach to exposing children to new drugs was to protect children from research. This has evolved over the past several decades into protecting...
6.
Offringa M, Davis J, Turner M, Ward R, Bax R, Maldonado S, et al.
Ther Innov Regul Sci
. 2018 Sep;
49(5):623-631.
PMID: 30227031
The First Annual Neonatal Scientific Workshop focused on the needs of the neonate by addressing the basic question: what information is required to inform decision making both at the regulatory...
7.
Davis J, Baer G, Portman R, Nelson R, Storari L, Aranda J, et al.
Clin Ther
. 2017 Oct;
39(10):1959-1969.
PMID: 28987269
Because the highest rates of morbidity and mortality in neonates are seen in those born at <32 weeks' gestation, this group has the most urgent need for novel therapies to...
8.
Turner M, Davis J, McCune S, Bax R, Portman R, Hudson L
Pediatr Res
. 2016 Jul;
80(4):462-4.
PMID: 27384407
No abstract available.
9.
Samardzic J, Turner M, Bax R, Allegaert K
Expert Opin Drug Metab Toxicol
. 2015 May;
11(7):1041-52.
PMID: 25958820
Introduction: The key feature of the newborn is its fast age-dependent maturation, resulting in extensive variability in pharmacokinetics and -dynamics, further aggravated by newly emerging covariates like treatment modalities, environmental...
10.
Bax R, Raue H, Vos J
RNA
. 2006 Oct;
12(11):2005-13.
PMID: 17018574
Slx9p (Ygr081cp) is a nonessential yeast protein previously linked genetically with the DNA helicase Sgs1p. Here we report that Slx9p is involved in ribosome biogenesis in the yeast Saccharomyces cerevisiae....